OTCM
VYCO
Market cap4mUSD
Jul 02, Last price
0.13USD
1D
-0.08%
Jan 2017
-61.17%
IPO
560.00%
Name
Vycor Medical Inc
Chart & Performance
Profile
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. Vycor Medical, Inc. has a license and transition agreement with HelferApp GmbH, which grants HelferApp the license to provide NovaVision's products and therapies to patients and professionals in Austria and Switzerland. The company primarily serves hospitals and medical professionals. Vycor Medical, Inc. was incorporated in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,461 19.43% | 1,223 -12.20% | |||||||
Cost of revenue | 168 | 141 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,293 | 1,082 | |||||||
NOPBT Margin | 88.53% | 88.50% | |||||||
Operating Taxes | 6 | ||||||||
Tax Rate | 0.57% | ||||||||
NOPAT | 1,293 | 1,076 | |||||||
Net income | (70) -82.83% | (406) -22.46% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 867 | 848 | |||||||
Long-term debt | 389 | 176 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (146) | ||||||||
Net debt | 1,199 | 986 | |||||||
Cash flow | |||||||||
Cash from operating activities | 29 | (217) | |||||||
CAPEX | (9) | (3) | |||||||
Cash from investing activities | (9) | (3) | |||||||
Cash from financing activities | 211 | 166 | |||||||
FCF | 1,560 | 1,496 | |||||||
Balance | |||||||||
Cash | 57 | 37 | |||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | (32,690) | (32,295) | |||||||
Invested Capital | 30,474 | 30,349 | |||||||
ROIC | 4.25% | 3.56% | |||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 32,604 | 31,708 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 1,354 | 1,144 | |||||||
EV/EBITDA | |||||||||
Interest | 103 | 92 | |||||||
Interest/NOPBT | 7.97% | 8.52% |